TABLE 1.
Cohort characteristics by study group. Wilcoxon rank sum test was used to test for homogeneity between study groups. The p-values can be found in column 5 respectively.
| Group 1 (n = 298) SARS-CoV-2 naive residents ≥ 75 years of age | Group 2 (n = 114) SARS-CoV-2 naive HCWs 18 to 70 years of age | Group 3 (n = 14) Residents with breakthrough infection | p-values group 1 Vs Group 2 group 1 Vs Group 3 | ||||
|---|---|---|---|---|---|---|---|
| Age at day of first vaccination [median] | 86 years | 53 years | 89 years | p1 vs. 2 < 0.001 | |||
| 108: 82.0 to 90.75, range: 75 to 101 | IQR: 45.25 to 59.75, range: 24 to 70 | IQR: 86.25 to 91, range: 82 to 93 | p1 vs. 3 = 0.11 | ||||
| Sex [% within each group] | 212 female (71.1%) | 83 female (72.8%) | 13 female (92.9%) | p1 vs. 2 = 0.74 | |||
| 86 male (28.9%) | 31 male (27.2%) | 1 male (7.1%) | p1 vs. 3 = 0.08 | ||||
| BMI [median] | 25.3 kg/m2 | 26.4 kg/m2 | 23.34 kg/m' | p1 vs. 2 = 0.14 | |||
| IQR: 22.4 to 28 6, range. 14.9 to 42.9 | IQR: 22.5 to 30.2, range: 18.0 to 50.0 | IQR: 20.5 to 28.6, range: 17.0 to 32,1 | p1 vs. 3 = 0.41 | ||||
| Interval between second vaccination and blood draw [median] | 6.49 months | 6.46 months | 7.13 months | p1 vs. 2 < 0.001 | |||
| range: 5,08 to 7.71 | range: 5.51 to 6.95 | range: 5.84 to 7.57 | |||||
| Interval between breakthrough infection and blood draw [median] | N.A. | N.A. | 3.69 months | N.A. | |||
| range: 0.66 to 6.55 | |||||||
| Anti-RBD-IgG antibody titer [mean] | 74.97 BAU/ml | 159.99 BAU/ml | 3,199.65 BAU/ml | p1 vs. 2 < 0.001, CI: 76.82 to -48.93 | |||
| 10R: 11.22 to 61.69, range: 0.09 to 3,385.75 | 10,R: 57.04 to 176.30, range: 5.61 to 2008.16 | IQR: 857.65 to 4,601.88, range: 58.73 to 11,350.00 | p1 vs. 3 < 0.001, CI: 2,706.83 to 884.39 | ||||
| Neutralization assay [titer, mode] | No neutralization | 269 (90.6%) | No neutralization | 78 (68.4%) | No neutralization | 2 (14.3%) | p1 vs. 2 < 0.001 |
| 1:10 (borderline) | 14 (4.7%) | 1:10 (borderline) | 16 (14.0%) | 1:10 (borderline) | 0 (0%) | p1 vs. 3 < 0.001 | |
| 1:20 | 5 (1.7%) | 1:20 | 12 (10.5%) | 1:20 | 0 (0%) | ||
| 1:40 | 3 (1.0%) | 1:40 | 6 (5.3%) | 1:40 | 1 (7.1%) | ||
| 1:80 | 0 (0%) | 1:80 | 2 (1.8%) | 1:80 | 4 (28.6%) | ||
| 1:150 | 3 (1.0%) | 1:160 | 0 (0%) | 1:160 | 2 (14.3%) | ||
| 1:320 | 2 (0.7%) | 1:320 | 0 (0 °A) | 1:320 | 2 (14.3%) | ||
| 1:640 | 1 (0.3%) | 1:640 | 0 (0%) | 1:640 | 1 (7.1%) | ||
| 1:1,280 | 0 (0%) | 1:1,280 | 0 (0%) | 1:1,280 | 2 (14.3%) | ||
| Charlson Comorbidity Index (CCI) [median index] | 6 | 1 | 6 | p1 vs. 2 < 0.001 | |||
| 1QR: 5 to 7, range: 3 to 14 | IQR: 0 to 2, range: 0 to 5 | IQR: 5 to 7.75, range: 4 to 12 | p1 vs. 3 = 0.039 | ||||
| Drug Derived Complexity Index (DDCI) [median index] | 5 | 0 | 8 | p1 vs. 2 < 0.001 | |||
| IQR: 2 to 8, range- −2 to 20 | IQR: 0 to 1, range: −7 to 6 | IQR: 6 to 10.5, range: 0 to 15 | p1 vs. 3 = 0.002 | ||||